US 11,993,645 B2
Compositions comprising R-Spondin (RSPO) surrogate molecules
Vincent Christopher Luca, Menlo Park, CA (US); and Kenan Christopher Garcia, Menlo Park, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 16/476,501
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Jan. 11, 2018, PCT No. PCT/US2018/013325
§ 371(c)(1), (2) Date Jul. 8, 2019,
PCT Pub. No. WO2018/132572, PCT Pub. Date Jul. 19, 2018.
Claims priority of provisional application 62/444,987, filed on Jan. 11, 2017.
Prior Publication US 2020/0024338 A1, Jan. 23, 2020
Int. Cl. C07K 16/18 (2006.01); A61K 38/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01)
CPC C07K 16/18 (2013.01) [C07K 14/5406 (2013.01); C07K 14/55 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01); C07K 2319/21 (2013.01); C07K 2319/81 (2013.01)] 10 Claims
 
1. An RSPO surrogate composition that comprises:
(i) a specific binding domain for RNF43 or ZNRF3, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody or antigen-binding fragment thereof; and
(ii) a cell-targeting domain, wherein the cell-targeting domain is a cytokine or growth factor that specifically binds a cell surface receptor.